22:59 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest the generic antibiotic nifuroxazide could help treat melanoma. In two human metastatic melanoma cell lines, nifuroxazide plus the BRAF inhibitor Zelboraf vemurafenib and the MEK inhibitor Mekinist trametinib...
00:07 , Sep 28, 2018 |  BC Innovations  |  Tools & Techniques

Deconstructing tox in immuno-oncology

The best route to improving preclinical toxicity in immunotherapies could lie in reverse translation, feeding clinical data back into the preclinical space to inform model development, rather than trying to guess a priori what the...
17:31 , Sep 26, 2018 |  BC Innovations  |  Distillery Techniques

Assay and screens; other

TECHNOLOGY: Cell-free assays; computational models A computational model based on mutations in plasma cell-free DNA (cfDNA) could help predict the time to progression in mCRC patients treated with anti-EGFR therapies. Construction of the model involves three...
01:21 , Sep 21, 2018 |  BC Innovations  |  Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
18:48 , Sep 7, 2018 |  BC Week In Review  |  Company News

Beigene, Springworks testing combo for solid tumors

SpringWorks Therapeutics LLC (New York, N.Y.) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) partnered to test a combination therapy in a Phase Ib trial to treat advanced solid tumors. The trial, which is slated to start in...
10:02 , Sep 6, 2018 |  BC Extra  |  Company News

BeiGene, SpringWorks testing combo for solid tumors

SpringWorks Therapeutics LLC (New York, N.Y.) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) partnered to test a combination therapy in a Phase Ib trial to treat advanced solid tumors. The trial, which is slated to start in...
15:49 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Cushing disease Patient sample and cell culture studies suggest the BRAF V600E inhibitor Zelboraf vemurafenib could help treat Cushing disease, which involves excessive cortisol production triggered by ACTH-secreting pituitary adenomas. In 91 tumor samples from...
17:06 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals July 26, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended approval...
22:08 , Jul 27, 2018 |  BC Extra  |  Company News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals Friday, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended approval of...
15:54 , Jul 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest inhibiting RXR could help treat melanoma. In a human melanoma cell line, the combination of a tool compound RXR inhibitor and Mekinist trametinib decreased colony formation and viability...